1 active not recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Active not recruiting 1 |
Follow Protein Kinase Inhibitors: new trials by email Literature Review of Protein Kinase Inhibitors trials Research Report on Protein Kinase Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Savolitinib vs. Sunitinib in MET-driven PRCC. Savolitinib, Sunitinib - Carcinoma, Carcinoma, Renal Cell | Phase 3 | Active not recruiting | AstraZeneca | 60 | 2017-07-25 | 2026-07-14 |
Carcinoma (1) · Carcinoma, Renal Cell (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Neoplasms by Site (1) · Urologic Neoplasms (1)
Adenocarcinoma (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Male Urogenital Diseases (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1)
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine (1) · Sunitinib (1)
AstraZeneca (1)
Brazil (1) · France (1) · Italy (1) · Russia (1) · South Korea (1) · Ukraine (1) · United States (1)
2016 (1)